Alector advances AL137 toward IND, reports Q2 2026 results
Alector said it selected AL137 as its lead anti-amyloid beta antibody and targets an IND submission in Q1 2027, while reporting $172.8 million in cash as of June 30, 2026.
SEC filing
Latest
2 stories